Department of Defense

Support for established neurofibromatosis researchers to lead a multi-institutional virtual academy mentoring early-career investigators. The program combines pilot research projects with structured mentorship to advance NF science and develop the next generation of research leaders.

The Army seeks innovative reconstructive transplant approaches to restore form and function for combat casualties with severe injuries. This concept award supports early-stage research and development of surgical techniques, biomaterials, or technologies to advance transplantation capabilities.

Accelerate translational research in Duchenne muscular dystrophy toward clinical applications. DoD supports advanced preclinical and clinical studies with flexible funding levels and partnership options to bridge promising discoveries into therapies.

Seeking early-stage research to develop novel therapies for Duchenne muscular dystrophy across all age groups, from infants to nonambulatory individuals. High-risk/high-reward studies with strong preliminary data that could accelerate near-term clinical outcomes.

DoD supports investigator-initiated neurofibromatosis research across all phases (excluding clinical trials) to advance understanding of NF disorders and improve patient care. Projects may leverage open science collaboration and qualified researcher partnerships to accelerate breakthroughs.

This award supports collaborative neurofibromatosis research teams (2-3 PIs) combining complementary expertise to tackle central NF problems. Applicants must demonstrate preliminary data and synergistic approaches to advance understanding and treatment of neurofibromatosis.

DoD seeks innovative, high-risk neurofibromatosis research projects that explore groundbreaking concepts and challenge existing paradigms. This award supports hypothesis development and early-stage exploration to establish foundations for future scientific investigation.

Support early-career researchers conducting innovative basic, translational, or clinical research on neurofibromatosis disorders. This Scholar Award develops the next generation of NF researchers within a collaborative academy environment with dedicated career mentorship.

Develop and test broadly applicable clinical technologies addressing urgent military health needs through translational research and early-phase clinical trials. Multi-PI teams will advance platform products that benefit Service Members, Veterans, and their families.

DoD seeks clinical trial research to advance treatment and management of military-relevant diseases. This peer-reviewed program funds trials from early-phase (Phase 0/1) through large-scale Phase 3 studies, with optional planning support for regulatory preparation.

This DoD funding supports innovative research to transform Alzheimer's diagnosis and disease monitoring. Projects must demonstrate non-incremental solutions that overcome barriers to diagnosis and prognosis, with preliminary data and community collaboration required.

This DoD program funds clinical research and trials testing new care interventions for Alzheimer's disease and related dementia. Projects must demonstrate preliminary data, involve community collaboration, and address practical care solutions beyond drug testing.

Supports transformative research to identify and validate risk factors for Alzheimer's disease and develop prevention strategies. Projects must advance understanding of environmental, genetic, or lifestyle risks and propose actionable solutions to reduce AD/ADRD development.

DoD seeks prototype development of an affordable, extended-range cruise missile (1,000+ nautical miles) costing under $300,000 per unit. The system must maintain precision strike capability and low-radar-signature survivability while using commercially available materials and modular design to solve critical munitions stockpile depth constraints.

Develop high-impact ideas advancing kidney cancer understanding and patient outcomes through well-formulated research hypotheses. Supports single or partnered investigator teams with strong kidney cancer research backgrounds.

This DoD program mentors early-career kidney cancer researchers through intensive virtual training, peer networking, and personalized mentorship. It aims to develop the next generation of cutting-edge kidney cancer researchers and accelerate discovery of new patient treatments.

DoD seeks groundbreaking novel concepts to advance rare cancer research and treatment. This concept award supports highly innovative, untested ideas without requiring preliminary data, enabling early-stage exploration of potentially transformative approaches.

This DoD award funds multidisciplinary, multi-institutional consortia addressing transformative breast cancer research challenges. Led by up to five PIs and consumer advocates, projects must tackle major problems requiring collaborative breakthroughs that single investigators cannot achieve.

DoD funds breakthrough breast cancer research advancing toward clinical trials, requiring multidisciplinary teams with consumer advocates. This Level 4 award targets high-impact discoveries ready for human testing and clinical application.

DoD seeks breakthrough breast cancer research with high clinical potential, supporting projects from preclinical through early clinical stages. Applications must address priority research challenges and include consumer advocates as core team members.

Develop ALS therapeutics from preclinical validation through FDA IND-enabling studies. This award accelerates drug candidates toward clinical testing while requiring parallel development of mechanism-specific biomarkers for improved patient selection and trial design.

This DoD funding supports high-risk, hypothesis-driven research to discover new ALS drugs and therapies. Applications emphasizing novel approaches can succeed without preliminary data, enabling bold therapeutic innovation.

Develop and validate clinical biomarkers and outcome measures to improve ALS clinical trials, including digital health tools like wearables and AI-enabled monitoring. Projects should incorporate patient community input and may target specific ALS subtypes or therapeutic classes.

This DoD funding supports rapid clinical trials testing new ALS treatments, from phase 1 through small phase 2 studies. Focus areas include biomarker-driven interventions and improved clinical care approaches for managing the disease.

DARPA BTO seeks novel biological technologies that revolutionize warfighter protection by leveraging biological properties and processes. Evolutionary improvements to existing practices are excluded; only truly innovative approaches will be considered.